Xenon Pharmaceuticals Inc. (XENE) News
Filter XENE News Items
XENE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XENE News Highlights
- XENE's 30 day story count now stands at 4.
- Over the past 16 days, the trend for XENE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BPMC are the most mentioned tickers in articles about XENE.
Latest XENE News From Around the Web
Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate UpdateBURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the close of U.S. financial markets on Tuesday, March 1, 2022. Conference Call/Webcast Information: Xenon will host a conference call and live audio webcast on Tuesday, March 1, 2022 at 4:30 pm Eastern Time (1:30 pm Pacific |
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue EstimatesBlueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceBURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. Fireside Chat Details: Date:Time:Presenter:Thursday, February 17, 20225:00-5:30 pm ETIan Mortimer, President and CEO The above listed dates and times are subject to change. Details on company pre |
How Did Hedge Funds’ Xenon Pharmaceuticals Inc (XENE) Bets Fare?The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […] |
Xenon draws buyout speculation after Zogenix dealDealreporter flags Xenon Pharmaceuticals < |
Accel Wealth Management Buys Vanguard Total Stock Market ETF, iShares Core Dividend Growth ETF, ...Investment company Accel Wealth Management (Current Portfolio) buys Vanguard Total Stock Market ETF, iShares Core Dividend Growth ETF, FIRST TR EXCHANGE, Vanguard Growth ETF, Recon Capital NASDAQ-100 Covered Call ETF, sells First Trust NASDAQ Clean Edge Green Energy Idx Fd, , Meta Platforms Inc, Vanguard Mortgage-Backed Securities ETF, BTC iShares U.S. |
Xenon passes regulatory mark to receive $15M from Neurocrine BiosciencesXenon Pharmaceuticals (XENE) reaches regulatory milestone to receive a payment of $15M from Neurocrine Biosciences (NBIX) under its collaboration to develop treatments for epilepsy. It |
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory MilestoneBURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. Food and Drug Administration (FDA) accepted Neurocrine’s protocol amendment that expands the study population to incl |
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We are entering 2022 with an immense amount of positive momentum, building upon the strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial announced in the fourth quarter of 2021. We have set clear business objectives f |
Xenon (XENE) Receives a Buy from Leerink PartnersLeerink Partners analyst Marc Goodman maintained a Buy rating on Xenon (XENE – Research Report) on December 17 and set a price target of $40.00. The company's shares closed last Wednesday at $29.18. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $45.14 average price target, implying a 52.8% upside from current levels. |